Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Know Labs Inc. (KNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: KNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -45.76% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.05M USD | Price to earnings Ratio - | 1Y Target Price 40 |
Price to earnings Ratio - | 1Y Target Price 40 | ||
Volume (30-day avg) 143763 | Beta 1.44 | 52 Weeks Range 0.55 - 34.80 | Updated Date 03/30/2025 |
52 Weeks Range 0.55 - 34.80 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -276.14% | Return on Equity (TTM) -1867.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5399690 | Price to Sales(TTM) 15.57 |
Enterprise Value 5399690 | Price to Sales(TTM) 15.57 | ||
Enterprise Value to Revenue 17.32 | Enterprise Value to EBITDA -3.51 | Shares Outstanding 2810600 | Shares Floating 2288716 |
Shares Outstanding 2810600 | Shares Floating 2288716 | ||
Percent Insiders 19.93 | Percent Institutions 5.52 |
Analyst Ratings
Rating 5 | Target Price 1 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Know Labs Inc.
Company Overview
History and Background
Know Labs, Inc., founded in 1998, is a medical technology company focused on developing non-invasive glucose monitoring technology. Initially focused on other technologies, the company pivoted to glucose monitoring. Key milestones include the development of its Bio-RFID sensor and ongoing clinical trials.
Core Business Areas
- Non-Invasive Glucose Monitoring: Development and commercialization of a non-invasive glucose monitoring device using radio frequency (RF) spectroscopy. This is their primary focus.
Leadership and Structure
Ronald K. Werner is the CEO. The company has a board of directors overseeing the management team. Organizational structure is typical of a development-stage medical device company.
Top Products and Market Share
Key Offerings
- Bio-RFID Sensor: Know Labs is developing a Bio-RFID sensor aimed at non-invasively measuring blood glucose levels. Market share is currently 0% as the product is pre-commercialization. Competitors include Abbott (ABT) with FreeStyle Libre, Dexcom (DXCM) with Dexcom G6 and G7, and Medtronic (MDT) with Guardian Sensor 3. These companies dominate the continuous glucose monitoring market.
Market Dynamics
Industry Overview
The glucose monitoring market is large and growing, driven by the increasing prevalence of diabetes. The market is shifting towards continuous glucose monitoring (CGM) devices.
Positioning
Know Labs aims to disrupt the market by offering a truly non-invasive solution, unlike current CGM devices which require a sensor inserted under the skin. Their competitive advantage, if successful, is the non-invasive nature of their technology.
Total Addressable Market (TAM)
The global diabetes care devices market is projected to reach hundreds of billions of dollars. Know Labs, if successful, is positioned to capture a substantial portion of the CGM market, which makes up a significant part of the TAM. Exact TAM figures vary based on source and projections, but are in the range of $25-$50 billion.
Upturn SWOT Analysis
Strengths
- Potentially disruptive non-invasive technology
- Large and growing market
- Strong patent portfolio
Weaknesses
- Pre-revenue stage
- Technology not yet commercially validated
- High risk of failure in clinical trials
- Limited financial resources
Opportunities
- Partnerships with diabetes device manufacturers
- Regulatory approval (FDA clearance)
- Expansion into other non-invasive monitoring applications
Threats
- Failure to obtain regulatory approval
- Technological challenges in achieving accurate and reliable readings
- Competition from established players with significant resources
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- Abbott (ABT)
- Dexcom (DXCM)
- Medtronic (MDT)
Competitive Landscape
Know Labs faces significant competition from established players with substantial resources. Its success depends on the superior performance and user experience of its non-invasive technology compared to existing CGM systems.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historically, the company has not had revenue. Growth is entirely dependent on future commercialization.
Future Projections: Future projections depend on clinical trial results and regulatory approval. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include completing clinical trials, seeking FDA clearance, and exploring partnerships.
Summary
Know Labs is a high-risk, high-reward company. Its non-invasive glucose monitoring technology holds significant promise, but faces substantial technological and regulatory hurdles. Success hinges on clinical trial results and FDA approval. The company's financial health depends on securing additional funding.
Similar Companies
- ABT
- DXCM
- MDT
Sources and Disclaimers
Data Sources:
- Know Labs SEC Filings (10-K, 10-Q)
- Industry Reports (Diabetes Care Market)
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Information is based on publicly available data, which may not always be accurate or up-to-date. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Know Labs Inc.
Exchange NYSE MKT | Headquaters Seattle, WA, United States | ||
IPO Launch date 2022-09-16 | Founder, CEO, Treasurer & Chairman Mr. Ronald P. Erickson J.D. | ||
Sector Technology | Industry Scientific & Technical Instruments | Full time employees 7 | Website https://www.knowlabs.co |
Full time employees 7 | Website https://www.knowlabs.co | ||
Know Labs, Inc., together with its subsidiaries, focuses on the development and commercialization of proprietary sensor technology by radio and microwave spectroscopy in the United States. The company involved in the identifying and measuring any material or analyte using electromagnetic energy to detect, record, identify, and measure the signature of said materials or analytes. The company was formerly known as Visualant, Incorporated and changed its name to Know Labs, Inc. in May 2018. Know Labs, Inc. was incorporated in 1998 and is based in Seattle, Washington.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.